Treatment Guides

Medicines for GVHD: Understanding Steroids, Ruxolitinib, Belumosudil and Later Treatment Options

After transplantation, the number of medicine containers can become difficult to manage. Some prescriptions treat GVHD, others prevent infection, and others address complications of treatment. Hearing that another patient has started a newer medicine may create concern that one's own regimen is outdated. In practice, drug selection depends first on the type of GVHD, the organs involved, previous response and the person's ability to tolerate treatment.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

  • A useful list identifies the generic name, formulation, prescribed amount, timing and reason for each medicine. Drugs taken together may have separate purposes: controlling immune injury, preventing a particular infection, managing stomach symptoms or supporting bone health. They are not all interchangeable “anti-rejection drugs,” and improvement in one GVHD symptom does not mean that they can all stop together.[1]
  • Axatilimab targets the CSF-1 receptor. US Niktimvo prescribing information covers adults and pediatric patients weighing at least 40 kilograms with chronic GVHD after failure of at least two systemic lines. It is given through a professional infusion service, with monitoring that includes liver-related tests, creatine phosphokinase and pancreatic enzymes. Feeling comfortable during the infusion alone does not establish that treatment is free of adverse effects.[10]
  • Differences in names, strengths and formulations can increase the chance of a prescribing error during international care. Before travel, establish exactly what product is being taken, how much supply remains and whether the receiving hospital can assess and continue treatment. Arrange who will review monitoring results after the patient returns home. Keep generic names alongside relevant Chinese names, rather than relying on a brand abbreviation alone.

Quick answer

After transplantation, the number of medicine containers can become difficult to manage. Some prescriptions treat GVHD, others prevent infection, and others address complications of treatment. Hearing that another patient has started a newer medicine may create concern that one's own regimen is outdated. In practice, drug selection depends first on the type of GVHD, the organs involved, previous response and the person's ability to tolerate treatment.

Full guide

After transplantation, the number of medicine containers can become difficult to manage. Some prescriptions treat GVHD, others prevent infection, and others address complications of treatment. Hearing that another patient has started a newer medicine may create concern that one's own regimen is outdated. In practice, drug selection depends first on the type of GVHD, the organs involved, previous response and the person's ability to tolerate treatment.

This guide explains the place of commonly discussed medicines and the information that helps a team prescribe safely. Sources were checked through September 2026. Country-specific indications, age limits and formulations differ; individual doses, interruptions and changes belong in a plan from the service responsible for transplant follow-up.

Read the medication list by purpose

A useful list identifies the generic name, formulation, prescribed amount, timing and reason for each medicine. Drugs taken together may have separate purposes: controlling immune injury, preventing a particular infection, managing stomach symptoms or supporting bone health. They are not all interchangeable “anti-rejection drugs,” and improvement in one GVHD symptom does not mean that they can all stop together.[1]

When attending another hospital, keep the packaging or clear photographs and record the date of the latest prescription change. Generic names and strengths help when brand names differ between countries. If old and new lists coexist, ask which is the current version so that different caregivers do not prepare medicines from conflicting instructions.

Report missed doses, vomiting and difficulty swallowing honestly. These details can affect the interpretation of response. Do not compensate for uncertain absorption by independently taking an extra dose. The pharmacy or treatment team should provide instructions appropriate to the actual product.

Corticosteroids remain important, and tapering is part of treatment

The 2026 ASTCT guideline continues to use systemic corticosteroids as the first-line foundation for acute GVHD requiring systemic therapy. Initial systemic treatment of chronic GVHD also commonly involves steroids, sometimes with other medicines. Their age as a treatment does not make them irrelevant; what matters is whether they control the current disease and whether their burden remains acceptable.[2,3]

Monitoring extends beyond the rash or bowel symptoms. Sleep, mood, muscle strength, glucose and infection concerns may also need attention. Tapering depends on disease control and treatment history, so another patient's weekly reduction schedule is not a personal prescription. MSK's prednisone information advises against sudden independent discontinuation and describes the need to discuss gradual reduction, particularly after longer use.[4]

Symptoms appearing during a taper do not automatically establish that the previous dose must continue indefinitely. The team needs to assess renewed GVHD activity, other illnesses and problems related to reducing treatment. A record showing when the dose changed and when symptoms began is easier to interpret than a general statement that tapering felt bad.

Ruxolitinib: match the indication to acute or chronic disease

Ruxolitinib is a JAK inhibitor. Chinese approval information includes acute or chronic GVHD in patients aged 12 years and older inadequately responding to corticosteroids or other systemic treatment. The 2026 ASTCT guideline identifies it as standard second-line treatment for steroid-refractory acute GVHD. That does not mean that all ages, grades and clinical circumstances use the same prescription.[2,5]

Blood-count suppression and infection are relevant concerns. Changes in hemoglobin, platelets or neutrophils may affect management, but dose decisions also depend on the GVHD setting, organ function and other medicines. A dosing table intended for myelofibrosis should not be copied into a personal GVHD plan merely because the drug name is identical.[6]

The US prescribing information updated in May 2026 includes both immediate-release Jakafi and extended-release Jakafi XR. This makes checking the formulation especially important. It does not show that the extended-release product is available in China, and it is not a reason for patients to convert their own tablets to a once-daily schedule.[6]

Belumosudil: use the Chinese label for Chinese eligibility

Belumosudil inhibits ROCK2. The Chinese prescribing information revised in January 2026 covers chronic GVHD in people aged 12 years and older who have responded inadequately to corticosteroids or other systemic treatment. It is not a general medicine for acute GVHD. The US requirement involving failure of at least two systemic lines should not simply replace the Chinese wording.[7,8]

The Chinese label specifies taking the intact tablet with food and monitoring liver tests. Proton pump inhibitors and other medicines may affect exposure or require an interaction-specific plan. A medicine taken for stomach symptoms therefore belongs on the full prescription list. Adjustments described in the label are for professional management, not an invitation to double treatment independently.[7]

Chronic GVHD may combine active inflammation with lasting tissue injury. Organ and functional assessment remain necessary after starting treatment. A mechanism involving fibrosis does not guarantee that every established scar or restriction will reverse. New deterioration in eating, movement or breathing should be reported even if another manifestation appears to be improving.

Ibrutinib: separate the GVHD indication from cancer information

Current US prescribing information includes ibrutinib for chronic GVHD in adults and children aged one year and older after failure of one or more systemic lines. The same label also discusses certain blood cancers, so patients should check that they are reading the GVHD section and the correct formulation information.[9]

Bleeding, infection, arrhythmias and blood-pressure problems are among the relevant safety considerations. Tell the team about planned dental work or other procedures so that any peri-procedural adjustment can be coordinated. Approval of a different BTK inhibitor for lymphoma does not establish that all medicines in that class can substitute for ibrutinib in GVHD.

This guide describes the US indication to clarify international discussions. The reviewed material does not establish the Chinese GVHD indication or supply arrangements for this use. If a hospital proposes it, ask for the local treatment basis, expected benefit and monitoring plan.

Axatilimab requires eligibility and infusion monitoring

Axatilimab targets the CSF-1 receptor. US Niktimvo prescribing information covers adults and pediatric patients weighing at least 40 kilograms with chronic GVHD after failure of at least two systemic lines. It is given through a professional infusion service, with monitoring that includes liver-related tests, creatine phosphokinase and pancreatic enzymes. Feeling comfortable during the infusion alone does not establish that treatment is free of adverse effects.[10]

In 2026, FDA challenged aspects of patient-facing promotion that could overstate its efficacy by implying complete responses. In the relevant approval assessment, the responders had partial responses.[11] A partial response can be valuable, but it does not mean every organ has returned to normal or that the condition has been cured.

When this medicine is raised during an international consultation, confirm the previous treatment history, weight and indication before discussing access. A US label is not evidence of routine Chinese supply, and promotional response claims should not be used to rank it above other therapies without appropriate comparative evidence.

Why other immunosuppressive medicines still appear

Calcineurin inhibitors, mycophenolate and other agents can appear at different points in transplantation and GVHD care. Their purpose may be prevention, combination treatment or later management. The team considers the existing regimen, organ involvement and tolerability. A medicine should not be removed solely because it receives less attention than a newly approved therapy.[3]

For medicines requiring blood-level monitoring, follow the service's instructions about the timing of the sample relative to the dose. Record whether the medicine was taken beforehand. A high or low result needs interpretation with sampling time, interactions and clinical findings; adjusting tablet numbers solely according to a laboratory arrow can be misleading.

Local treatments may remain necessary as well. Eye, mouth or skin prescriptions address specific manifestations and may have a different stopping plan from systemic therapy. Changes in comfort are useful information, but they do not replace examination where an organ is at risk. When care changes hospitals, provide the recent medication levels and the conditions under which they were measured.

Supportive medicines have their own indications

Infection prevention during GVHD treatment depends on factors such as transplant timing, immune suppression, infection history and local circumstances. Some preventive medicines are intended to be taken when the patient feels well; absence of fever does not establish that they are unnecessary. Fever, persistent cough, a new rash or significant diarrhea also needs assessment rather than automatic attribution to a GVHD flare.[1]

Other prescriptions address treatment-related problems involving bone health, glucose or gastrointestinal symptoms. Asking why each medicine is still needed can identify outdated instructions while preserving appropriate protection. Selectively missing tablets because the list seems too long makes the actual regimen difficult for the team to reconstruct.

A medication review should be a conversation about necessity and feasibility. Tell the pharmacist if the schedule interferes with eating, sleep or work, or if packaging is difficult to read. The team may be able to clarify or simplify arrangements while maintaining the treatment purpose. Quietly improvising a different routine removes the opportunity to solve the underlying problem.

Give each new prescription an assessment plan

At the start of treatment, establish what the team expects to follow. The main target may be bowel symptoms, skin involvement, oral intake, lung function, liver tests or movement. Different organs can respond differently, and infection or toxicity may affect the same measures. NIH response guidance distinguishes organ response from overall response; improvement in one site should not obscure progression elsewhere.[12]

A short record of relevant changes is often more helpful than a complicated home scoring system. If swallowing is the main issue, record what can be eaten and the weight trend. If tissue tightness limits daily activity, record the specific tasks affected. Ask which changes require contact before the next planned visit.

The appointment date is not a requirement to wait through significant deterioration. Equally, lack of an immediate visible change does not automatically justify abandoning a medicine. A review that includes the current organ findings, adverse effects and actual doses taken gives the prescriber a sounder basis for the next decision.

Protect continuity when seeking care in China

Differences in names, strengths and formulations can increase the chance of a prescribing error during international care. Before travel, establish exactly what product is being taken, how much supply remains and whether the receiving hospital can assess and continue treatment. Arrange who will review monitoring results after the patient returns home. Keep generic names alongside relevant Chinese names, rather than relying on a brand abbreviation alone.

A valid RMB estimate requires a specific product, quantity and date from the hospital or pharmacy. A price for one box found online does not establish the cost of the full course. Necessary visits, laboratory tests and infusion services may also contribute. Duration and the possibility of dose reduction or replacement depend on the clinical course; purchasing a supply does not set a guaranteed date for stopping all treatment.

A clear medication plan allows the patient to explain why the current regimen is being used, recognize the problems that need attention and know who will make the next decision. That practical understanding supports safer daily care and makes communication between teams much easier.

References

  1. NIH. Ancillary Therapy and Supportive Care Working Group Report: https://pmc.ncbi.nlm.nih.gov/articles/PMC4821166/
  2. ASTCT. Acute GVHD treatment guideline, 2026: https://pubmed.ncbi.nlm.nih.gov/42155643/
  3. EBMT Handbook. Chronic Graft-Versus-Host Disease, 2024: https://www.ncbi.nlm.nih.gov/books/NBK608236/
  4. MSK. Prednisone: https://www.mskcc.org/cancer-care/patient-education/medications/adult/prednisone
  5. Novartis China. Ruxolitinib GVHD indication information: https://www.novartis.com.cn/news/jiekewei-linsuanluketinipianzhiliaomanxingyizhiwukangsuzhubingxinshiyingzhengzaihuahuopi
  6. FDA. Jakafi/Jakafi XR prescribing information, May 2026: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217180s001lbl.pdf
  7. Belumosudil Chinese prescribing information, January 22, 2026: https://www.sanofi.cn/assets/dot-cn/pages/docs/products/prescription-products/rezurock-cn-20260122.pdf
  8. FDA approval summary for belumosudil: https://pmc.ncbi.nlm.nih.gov/articles/PMC9197942/
  9. DailyMed. Current US Imbruvica prescribing information: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0dfd0279-ff17-4ea9-89be-9803c71bab44
  10. DailyMed. Current US Niktimvo prescribing information: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bb6dba23-e7a6-4765-a1e6-b9e277ce0381&type=display
  11. FDA. Niktimvo promotional communication letter, 2026: https://www.fda.gov/media/192125/download?attachment=
  12. NIH. 2014 chronic GVHD response criteria: https://pmc.ncbi.nlm.nih.gov/articles/PMC4744804/

Related guides